The value and limits of artificial intelligence in perioperative immunotherapy for gastric cancer
Authors:
- Xin XinXXXin Xin
- Yan LiYLYan Li
- Guoliang ZhengGZGuoliang Zheng
Open Access
- 1 January 2026
- journal article
- Published by Innovation Press Co., Limited in The Innovation Oncology
- Vol. 1 (2) , 100019-1-100019-2
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 StudyJournal of Clinical Oncology, 2025
- Perioperative Durvalumab in Gastric and Gastroesophageal Junction CancerNew England Journal of Medicine, 2025
- Multimodal radiopathomics signature for prediction of response to immunotherapy-based combination therapy in gastric cancer using interpretable machine learningCancer Letters, 2025
- TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methodsBMJ, 2024
- Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 TrialJournal of Clinical Oncology, 2024